Summary by Futu AI
China Biopharmaceuticals Limited (“China Biopharmaceuticals”) recently announced that its independently developed class 1 innovative drug “TQA3038 (siRNA)” has successfully completed Phase I clinical trials. TQA3038 is a small interfering RNA drug against hepatitis B virus (HBV) with good safety and tolerability and exhibits pharmacokinetic characteristics consistent with non-clinical pharmacokinetics. The drug uses an autonomous proprietary nucleic acid sequence and exhibits stronger antiviral activity in body and in body than other siRNA drugs. China Biopharmaceutical Program has recently launched a follow-up clinical study of TQA3038 in patients with chronic hepatitis B. The Chairman of the Board of Directors of the Company, Mr. Xie Yun, made this announcement on April 25, 2024.